Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361 (http://www.ncbi.nlm.nih.gov/pubmed/36017568).

Article  PubMed  Google Scholar 

He X, Ji J, Dai X, Qdaisat AZ, Esteva FJ, Hortobagyi GN, et al. Association of cardiovascular disease risk factors with late cardiotoxicity and survival in HER2-positive breast cancer survivors. Clin Cancer Res. 2021;27(19):5343–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC: CardioOncology. 2019;1(2):208–17.

PubMed  PubMed Central  Google Scholar 

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99.

Article  PubMed  Google Scholar 

Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911.

Article  PubMed  Google Scholar 

Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60 (http://www.ncbi.nlm.nih.gov/pubmed/32463967).

Article  PubMed  Google Scholar 

McCracken C, Condurache DG, Szabo L, Elghazaly H, Walter FM, Mead AJ, et al. Predictive performance of cardiovascular risk scores in cancer survivors from the UK Biobank. JACC: CardioOncology. 2024;6(4):575–88.

PubMed  PubMed Central  Google Scholar 

Zhang X, Pawlikowski M, Olivo-Marston S, Williams KP, Bower JK, Felix AS. Ten-year cardiovascular risk among cancer survivors: the National Health and Nutrition Examination Survey. PLoS One. 2021;16(3):e0247919.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life’s essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):E18-43. https://doi.org/10.1161/CIR.0000000000001078.

Article  PubMed  PubMed Central  Google Scholar 

Wadden E, Vasbinder A, Yogeswaran V, Shadyab AH, Saquib N, Sun Y, et al. Life’s essential 8 and incident cardiovascular disease in U.S. women with breast cancer. JACC: CardioOncology. 2024;6(5):746–57.

PubMed  PubMed Central  Google Scholar 

Stabellini N, Makram OM, Kunhiraman HH, Daoud H, Shanahan J, Montero AJ, et al. A novel machine learning-based cancer-specific CVD risk score among patients with breast, colorectal, or lung cancer. JNCI Cancer Spectr. 2025;9(1):pkaf016.

Article  PubMed  PubMed Central  Google Scholar 

Kaboré EG, Macdonald C, Kaboré A, Didier R, Arveux P, Meda N, et al. Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: a systematic review. JAMA Netw Open. 2023;6(2):e230569–e230569. https://doi.org/10.1001/jamanetworkopen.2023.0569.

Article  PubMed  PubMed Central  Google Scholar 

Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Martínez Monzonis A, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025;46(3):273–84.

Article  PubMed  CAS  Google Scholar 

Di Lisi D, Madaudo C, Alagna G, Santoro M, Rossetto L, Siragusa S, et al. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail. 2022;9(3):1914–9.

Article  PubMed  PubMed Central  Google Scholar 

Kim DY, Park MS, Youn JC, Lee S, Choi JH, Jung MH, et al. Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: the chemo-radiat score. J Am Heart Assoc. 2021;10(16):e021931.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vasbinder A, Catalan T, Anderson E, Chu C, Kotzin M, Murphy D, et al. Cardiovascular risk stratification of patients undergoing hematopoietic stem cell transplantation: the CARE-BMT risk score. J Am Heart Assoc. 2024;13(1):e033599. https://doi.org/10.1161/JAHA.123.033599.

Article  PubMed  CAS  Google Scholar 

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Goncalves Brandao SM, Rigaud VO, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281–90.

Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62 (http://www.ncbi.nlm.nih.gov/pubmed/23583763).

Article  PubMed  CAS  Google Scholar 

Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1544–9 (http://www.ncbi.nlm.nih.gov/pubmed/34436523).

Article  PubMed  Google Scholar 

Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017Mar 10;35(8):870–7.

Article  PubMed  CAS  Google Scholar 

Austin D, Maier RH, Akhter N, Sayari M, Ogundimu E, Maddox JM, et al. Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial. JACC CardioOncol. 2024;6(5):684–96 (http://www.ncbi.nlm.nih.gov/pubmed/39479329).

Article  PubMed  PubMed Central  Google Scholar 

Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-Year results of the SUCCOUR trial. JACC Cardiovasc Imaging. 2023;16(3):269–78.

Article  PubMed  Google Scholar 

Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. 2024;45(41):4414–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143(25):2431–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018;94:126–37.

Article  PubMed  CAS  Google Scholar 

Mecinaj A, Vinje-Jakobsen V, Ngo DTM, Sverdlov AL, Myhre PL. The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev. 2025. https://doi.org/10.1007/s10741-025-10495-1.

Article  PubMed  PubMed Central  Google Scholar 

Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81–9.

Article  PubMed  CAS  Google Scholar 

Abdel-Qadir H, Carrasco R, Austin PC, Chen Y, Zhou L, Fang J, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC: CardioOncology. 2023;5(3):318–28.

PubMed  PubMed Central